Medifast Q1 FY26: revenue $76.0M, down 34%; diluted EPS −$0.19

Key figures from this report

These are the numbers Medifast reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$76.0M−34% from $115.7M in Q1 FY2510-Q income statement, on EDGAR
2. Net income−$2.1MAgainst −$772K in Q1 FY2510-Q income statement, on EDGAR
3. Diluted EPS−$0.19Against −$0.07 in Q1 FY2510-Q income statement, on EDGAR
4. Cash and cash equivalents$71.5M−22% from $91.7M in Q1 FY25Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
5. Cash from operations$260K−92% from $3.4M in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables